InvestSMART

Imugene Limited (ASX:IMU)

ALERT: Price-sensitive ASX Announcement for IMU
Current share price for IMU : $0.085 -0.005 (-5.56%)+
Announcement
Release
27 Jul 2026 9:55AM
Price at Release
$0.090
Full Release
download
Summary
Imugene Limited reported a third patient response in the concurrent BTKi cohort of its azer-cel Phase 1b clinical trial. This cohort involves patients with Follicular Lymphoma (FL) who have relapsed on or are refractory to Bruton Tyrosine Kinase inhibitor (BTKi) therapy. The trial aims to evaluate if concurrent dosing of azer-cel with a BTKi can restore or enhance therapeutic activity. The third response was a partial response in a patient who had previously progressed on BTKi therapy. The trial is ongoing across multiple sites in the U.S. and Australia, addressing the unmet need in FL treatment where resistance to BTKi therapy is common. The global BTKi market was valued at approximately US$12.0 billion in 2025, highlighting the potential impact of this treatment approach.
Key Points
  • Third response in BTKi cohort of azer-cel Phase 1b trial
  • Partial response in Follicular Lymphoma patient
  • Concurrent dosing of azer-cel with BTKi being evaluated
  • Five patients dosed in the BTKi cohort
  • Unmet need in FL treatment due to BTKi resistance
  • Global BTKi market valued at US$12.0 billion in 2025
  • Ongoing trial across U.S. and Australia
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.